Company Description
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia.
The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 "VEGFR-3", currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema.
The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015.
Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
| Country | Australia |
| IPO Date | Oct 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Dr. Frederic Guerard M.S., Pharm.D. |
Contact Details
Address: Level 4, 650 Chapel Street South Yarra, Victoria, C3 3141 Australia | |
| Phone | 61 3 9826 0399 |
| Website | opthea.com |
Stock Details
| Ticker Symbol | OPT |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| IPO Price | $13.50 |
| CIK Code | 0001815620 |
| CUSIP Number | 68386J208 |
| ISIN Number | US68386J2087 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. | Founder, Chief Innovation Officer and Executive Director |
| Judith J. Robertson B.A., M.B.A. | Chief Commercial Officer |
| Karen Adams CPA | Vice President of Finance and Company Secretary |
| Dr. Frederic Guerard M.S., Pharm.D. | Chief Executive Officer |
| Peter F. Lang M.B.A. | Chief Financial Officer |
| Sarika Gulhar Ph.D. | Executive Director of Human Resources |
| Dr. Michael Gerometta Ph.D. | Head of Chemistry, Manufacturing and Controls Development |
| Bruno Gagnon BPHARM, M.Sc. | Senior Vice President of Global Clinical Operations |
| Dr. Kenneth Sall | Chief Medical Officer |
| Dr. Fang Li Ph.D. | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 1, 2024 | 6-K | Report of foreign issuer |
| Apr 30, 2024 | 6-K | Report of foreign issuer |
| Apr 25, 2024 | 6-K | Report of foreign issuer |
| Apr 9, 2024 | 6-K | Report of foreign issuer |
| Apr 5, 2024 | 6-K | Report of foreign issuer |
| Apr 5, 2024 | 6-K | Report of foreign issuer |
| Apr 4, 2024 | 6-K | Report of foreign issuer |
| Apr 3, 2024 | 6-K | Report of foreign issuer |
| Mar 19, 2024 | 6-K | Report of foreign issuer |
| Mar 6, 2024 | 6-K | Report of foreign issuer |